Navigation Links
Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/10/2009

ent, multi-center, randomized, double-blind, single-dose, placebo-controlled study intended to enroll 360 patients who have migraines, with or without aura. Two dose levels of AZ-104 are being evaluated in the clinical trial, 1.25mg and 2.5 mg. The primary efficacy endpoint for the trial is headache pain relief at 2 hours post-dose, using the standard IHS 4-point rating scale. Secondary efficacy endpoints for the trial include pain relief and other symptom assessments at various time points. Safety evaluations will also be made throughout the clinical trial period.

AZ-104 has been licensed to Symphony Allegro, and the Company has the right to repurchase all rights to this product candidate

  • AZ-001 (Staccato prochlorperazine). Alexza is developing AZ-001 to treat patients suffering from acute migraine headaches. During the third quarter of 2008, Alexza conducted an end-of-Phase 2 meeting with the FDA. The Company believes it has a clear understanding of the development requirements for filing an NDA for this product candidate. Consistent with previous guidance, Alexza is not planning on conducting any AZ-001 Phase 3 studies without a partner, and is continuing to seek partners for the Staccato migraine product candidates, AZ-001 and AZ-104.
  • AZ-007 (Staccato zaleplon). Alexza is developing AZ-007 for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. AZ-007 has completed Phase 1 testing. No additional work is currently planned on AZ-007 for 2009 without a partner.
  • AZ-003 (Staccato fentanyl). Alexza is developing AZ-003 for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes. In January 2009, Alexza mutually agreed with
    '/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
2. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
5. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
6. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
7. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
10. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
11. Alexza to Webcast Investor and Analyst Day Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
... PhD.,co-founder and Chief Scientific Officer of Posit Science, has ... announcement by the Institute,today. Dr. Merzenich is one of ... a highly selective process that recognizes,people who have made ... care, and public health. Election is considered one of ...
... Oct. 13 The 2008 NCPA Digest,sponsored by ... 110th Annual,Convention. The Digest has been published annually ... portrait of the financial state of,independent community pharmacy ... an inside look into how the Medicare Part ...
... Knowledge Sharing among Physicians, MOUNTAIN VIEW, Calif., ... the healthcare IT market, Frost & Sullivan recognizes,Infor-Med, ... Sullivan Award for,Technology Innovation for its novel Praxis(R) ... EMR Knowledge Exchanger., The Praxis(R) EMR system ...
... 13 NeoVista, Inc., presented,yesterday the anatomic ... on choroidal neovascular lesions in an analysis ... 26th Annual Meeting. The,12-month data presented by ... Houston, Texas, demonstrated anatomic improvements on both,angiography ...
... neonatology fellows have been awarded grants designed to ... follow-up care of the premature infant as part ... MedImmune,s commitment to expanding research within pediatric medicine, ... totaling $175,000 in research funding. The five recipients ...
Cached Medicine News:Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:Merzenich Elected to Institute of Medicine 2Health News:Merzenich Elected to Institute of Medicine 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
(Date:1/23/2015)... Fla. , Jan. 23, 2015  iMD Companies, Inc. (ICBU) ... to increase market share and grab a foothold in the ... influence, production capabilities and a presence in the sector, and ... facilitate the growth of hemp and medical marijuana, iMD is ...
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... PARK, Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex Pharmaceuticals ... new clinical data relevant to the development,strategy ... the T315I mutation in Philadelphia-positive leukemias",by researchers ... of,Bologna, Italy (Haematologica Volume 92, pages 401-404) ...
... synergy, activity and patient tolerance observed in ... continuous,delivery therapy, WASHINGTON, May 21, 2007 /PRNewswire/ ... company, today announced,the presentation of final results ... of injectable omega interferon and ribavirin to,omega ...
Cached Medicine Technology:Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 2Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 4
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: